Overcoming prostate cancer drug resistance with a novel organosilicon small molecule
A major challenge to the treatment of advanced prostate cancer (PCa) is the development of resistance to androgen-deprivation therapy (ADT) and chemotherapy. It is imperative to discover effective therapies to overcome drug resistance and improve clinical outcomes. We have developed a novel class of...
Guardado en:
Autores principales: | Rui Zhao, Xiaowei Ma, Lijuan Bai, Xin Li, Kenza Mamouni, Yang Yang, HongYan Liu, Alira Danaher, Nicholas Cook, Omer Kucuk, Robert S. Hodges, Lajos Gera, Daqing Wu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1f6b060eb516456db0aa542c6160f224 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Human Cytomegalovirus-Infected Glioblastoma Cells Display Stem Cell-Like Phenotypes
por: Che Liu, et al.
Publicado: (2017) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016) -
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Sumanta Kumar Pal, et al.
Publicado: (2010) -
Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer
por: Huan Xu, et al.
Publicado: (2021) -
An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Josephina P. M. Vrouwe, et al.
Publicado: (2021)